6 Signs You May Need a Liver Ultrasound

How Doctors Decide Whether Ultrasound Is Appropriate

There is no universal symptom checklist that automatically determines who needs liver imaging. Some of the strongest reasons for ordering ultrasound are findings you would not notice without an examination or laboratory testing. That is why the word “signs” in this article includes symptoms, physical findings, and blood-test patterns.

A clinician first considers the question the scan is expected to answer. Your medical history, symptoms, physical examination, liver chemistries, metabolic history, and earlier test results may all affect that decision. Ultrasound can provide useful structural information, but it is not a universal answer to every liver concern.

The pattern of abnormal liver chemistries is particularly important. An increase dominated by ALT or AST raises different questions from elevated alkaline phosphatase or conjugated bilirubin. The American College of Gastroenterology recommends confirming abnormal liver chemistries and assessing their pattern. The American College of Radiology rates abdominal ultrasound as usually appropriate initial imaging in several hepatocellular, cholestatic, and hyperbilirubinemic presentations.

Imaging is therefore one part of an evaluation, not a diagnosis in itself. Depending on the question, a doctor may combine ultrasound with repeated blood tests, additional laboratory studies, elastography, or another imaging method. Having one of the signs below does not guarantee that ultrasound is necessary, while having none of them does not rule out liver disease.

For a patient-focused explanation of the procedure, preparation, and possible findings, review what a liver ultrasound evaluates.

Routine ultrasound can provide information about liver structure and may show fat in the liver. That makes it a useful initial examination for selected patients. It should not be presented as a test that independently diagnoses every cause of abnormal liver chemistries or explains every upper-abdominal symptom.

NIDDK states that routine imaging can show hepatic fat but cannot show the inflammation or fibrosis needed to distinguish simple steatosis from steatohepatitis. Current terminology uses metabolic dysfunction-associated steatotic liver disease, or MASLD, and metabolic dysfunction-associated steatohepatitis, or MASH. Older sources may use NAFLD and NASH.

Elastography is a separate technique that may be used to assess liver stiffness as a surrogate for fibrosis. NIDDK states that biopsy is the only test that can prove steatohepatitis and clearly show its severity. Neither elastography nor biopsy is required for every patient; their use depends on what remains uncertain after the clinical assessment, blood tests, and imaging are reviewed.

Ultrasound may also identify a finding that needs more specific imaging. If surveillance ultrasound detects a suspicious liver lesion, American Association for the Study of Liver Diseases guidance supports contrast-enhanced CT or MRI for diagnosis and characterization. In that situation, ultrasound has identified a question that it cannot answer definitively on its own.

Not ordering ultrasound immediately does not necessarily mean a concern is being dismissed. The first useful step may be to confirm a laboratory abnormality, separate bilirubin into its components, review earlier results, or determine whether the pattern is predominantly hepatocellular or cholestatic. That groundwork can make later imaging more purposeful.

A normal scan should not automatically end the evaluation when liver chemistries or other clinical concerns remain unexplained. Liver blood tests are indirect markers, and routine imaging cannot answer every question about liver disease. A clinician may need to reconcile the scan with laboratory findings and the rest of the clinical picture.

The goal is not to order as many tests as possible. It is to select the test most likely to answer the current question while acknowledging its limits. Knowing why a scan is being ordered also makes the result easier to discuss.

A diagnostic ultrasound investigates a current concern, such as an abnormal liver-test pattern, jaundice, suspected hepatobiliary pain, or organ enlargement. It may be a one-time examination or one step in a broader workup. Its timing and any follow-up depend on why it was ordered and what it shows.

Surveillance has a different purpose. American Association for the Study of Liver Diseases guidance recommends hepatocellular carcinoma surveillance for adults with established cirrhosis using ultrasound, with or without alpha-fetoprotein, every six months. This is a planned, recurring process rather than a response to a newly developed symptom.

That schedule should not be extended to everyone with metabolic risk factors or suspected fatty liver. Evaluation for possible MASLD is not the same as surveillance for a person with established cirrhosis. A clinician determines whether the surveillance recommendation applies to the individual.

If surveillance ultrasound finds a suspicious lesion, contrast-enhanced CT or MRI may be necessary for characterization. Ultrasound remains an important part of the surveillance pathway, but it is not the final diagnostic study for every liver lesion.

Bring complete laboratory reports if they are available rather than relying on a message that your “liver enzymes were high.” The individual ALT, AST, alkaline phosphatase, and bilirubin values-and the pattern they form-may influence whether the next step is confirmation, more laboratory evaluation, ultrasound, or another approach.

Describe any symptom as precisely as you can: where it occurs, when it began, whether it returns, and whether jaundice appeared at the same time. Share relevant medical history and earlier imaging. If fatty liver is being considered, your clinician may ask about diabetes, body-weight history, lipid abnormalities, hypertension, insulin resistance, or metabolic syndrome.

Ask what specific question the ultrasound is intended to answer. You can also ask what a normal or limited result would mean and whether further evaluation might still be considered if laboratory abnormalities continue.

• Bring exact results. Different liver-chemistry patterns can lead to different evaluation pathways.
• Describe symptoms clearly. Location, timing, recurrence, and associated findings provide important context.
• Share relevant history. Metabolic-risk features and established liver disease can change the reason for imaging.
• Bring earlier reports. Prior laboratory and imaging results may show whether a finding is new or already under evaluation.
• Ask about the purpose. Find out whether the scan is for initial evaluation, follow-up, or cirrhosis surveillance.
• Discuss possible next steps. Ask how normal, limited, or abnormal findings would affect the rest of your evaluation.

• Ultrasound does not use ionizing radiation. The FDA describes diagnostic ultrasound as using non-ionizing energy.
• Prudent use still matters. The FDA reports an excellent safety record when ultrasound is used prudently by appropriately trained providers, while noting that unnecessary prolonged exposure should be avoided.
• Visualization can vary. Body habitus, bowel gas, and operator expertise may affect image quality, so a scan may not adequately answer every clinical question.
• A normal result has limits. Normal imaging does not remove the need to assess persistent laboratory abnormalities or other ongoing clinical concerns.
• Different questions may require different tests. Elastography may assess liver stiffness, while suspicious lesions found during surveillance may require contrast-enhanced CT or MRI.
• Urgent liver dysfunction is not a routine imaging issue. Acute hepatitis with prolonged prothrombin time or encephalopathy requires immediate specialist referral rather than waiting for a scheduled scan.